MedTrace Logo

Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure

NCT06319274 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2025-08-22

No results posted yet for this study

Summary

The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.

Conditions

  • Acute Respiratory Failure
  • Endothelial Dysfunction
  • Pulmonary Infection

Interventions

DRUG

Iloprost

Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min

DRUG

Isotonic saline

Continuously infusion for 72 hours at 3 ml/hours

Sponsors & Collaborators

  • Pär Johansson

    lead OTHER

Principal Investigators

  • Pär I Johansson, MD, DMSc · Rigshospitalet, Denmark

  • Peter Soee-Jensen, MD · +4538682458

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319274 on ClinicalTrials.gov